Verve Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming to permanently lower LDL cholesterol with one treatment.
About
Verve Therapeutics is a clinical-stage genetic medicines company founded in 2018 by Andrew Bellinger and Sekar Kathiresan, focused exclusively on using base editing to treat cardiovascular disease. The company is developing one-time treatments that permanently lower LDL cholesterol and triglycerides by editing genes in liver cells that regulate lipid metabolism, including PCSK9 and ANGPTL3. Verve's approach targets the root cause of common cardiovascular disease rather than requiring lifelong daily medication, with the goal of a single infusion delivering durable benefit. The lead program VERVE-101 targets PCSK9 in liver cells and has entered Phase 1b clinical trials, with early data showing substantial and durable LDL reductions in patients with heterozygous familial hypercholesterolemia. Verve is publicly traded on Nasdaq and has established partnerships with Vertex Pharmaceuticals to advance the cardiovascular base editing pipeline. The company represents a fundamentally new approach to preventing heart attacks and strokes at the genetic level.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.